News | February 05, 2022
Mangalam Drugs and Organics Q3FY22 PAT at Rs. 4.02 crore
Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021
Mangalam Drugs and Organics Limited has reported standalone financial results for the period ended December 31, 2021
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
Subscribe To Our Newsletter & Stay Updated
